Biological
Sturlimogene erparepvec clinical trials
Also written RP2.
- studies test it
- 7
- open now
- 5
- in phase 3
- 1
- first study started
- 2023
Keep track of what changes. Save the sturlimogene erparepvec studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 7
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 4
Replimune, Inc. (3) · Yana Najjar (1) · Abramson Cancer Center at Penn Medicine (1) · Glenn J. Hanna (1) · City of Hope Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses sturlimogene erparepvec is read from its arms, and is right about nine times in ten.
Testing it · 7
- Neoadjuvant RP2 + Nivolumab in Patients With MelanomaNot yet recruitingPhase 2Yana NajjarNCT07862530Written as RP2 (vusolimogene oderparepvec)
- Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal AdenocarcinomaNot yet recruitingPhase 2Abramson Cancer Center at Penn MedicineNCT07059611Written as RP2
- Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous DiseaseRecruitingPhase 2Glenn J. HannaNCT06623110Written as RP2 Injection
- A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaRecruitingPhase 2/3Replimune, Inc.NCT06581406Written as RP2
- Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCRecruitingPhase 2Replimune, Inc.NCT05733598Written as RP2
- RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyWithdrawnPhase 2City of Hope Medical CenterNCT07218692Written as Sturlimogene Erparepvec
- RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCTerminatedPhase 2Replimune, Inc.NCT05733611Written as RP2
Given in every arm · 1 — sturlimogene erparepvec is usual care beside what is tested
Codes
What other systems call sturlimogene erparepvec · ClinicalTrials.gg INT014986
- UNII (FDA) 53Z5E7R5KDSTURLIMOGENE ERPAREPVECOne source FDA
- NCI Thesaurus C176748Sturlimogene ErparepvecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 53Z5E7R5KD | STURLIMOGENE ERPAREPVEC | One source FDA |
| NCI Thesaurus | C176748 | Sturlimogene Erparepvec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.